The National Institute for Food and Drug Surveillance —Invima— approved, through resolution No. 2022002030 of January 21, 2022, the emergency use of the new recombinant vaccine against coronavirus Zifivax.
The health authority indicated that the permit will be granted for a term of one year and a total of three injections to each recipient at an interval of one month, one dose per injection. The population that can access this biological will be from 18 years onwards.
–
